Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Feb;68(2):760-6.
doi: 10.1128/IAI.68.2.760-766.2000.

Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii

Affiliations

Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii

S Ricci et al. Infect Immun. 2000 Feb.

Abstract

The B monomer of the Escherichia coli heat-labile toxin (LTB) was expressed on the surface of the human oral commensal bacterium Streptococcus gordonii. Recombinant bacteria expressing LTB were used to immunize BALB/c mice subcutaneously and intragastrically. The LTB monomer expressed on the streptococcal surface proved to be highly immunogenic, as LTB-specific immunoglobulin G (IgG) serum titers of 140,000 were induced after systemic immunization. Most significantly, these antibodies were capable of neutralizing the enterotoxin in a cell neutralization assay. Following mucosal delivery, antigen-specific IgA antibodies were found in feces and antigen-specific IgG antibodies were found in sera. Analysis of serum IgG subclasses showed a clear predominance of IgG1 when recombinant bacteria were inoculated subcutaneously, while a prevalence of IgG2a was observed upon intragastric delivery, suggesting, in this case, the recruitment of a Th1 type of immune response.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Immunoblot analysis of the surface proteins of recombinant S. gordonii. The envelope fractions of recombinant strain GP1246, expressing the M6-LTB fusion protein (lanes 1), and of control strain GP1221.1 (lanes 2) were analyzed by Western blotting. The arrows indicate a major protein band of 44 kDa (the expected molecular mass of the recombinant protein was 41 kDa) that was found to be reactive with both anti-M6 (panel A) and anti-LTB (panel B) polyclonal antibodies. The positions of the molecular weight standards are indicated on the left (in kDa).
FIG. 2
FIG. 2
ELISA titers of serum LTB-specific total IgG following s.c. (A) and i.g. (B) immunizations with recombinant S. gordonii. Two groups of eight BALB/c mice each were inoculated s.c. at weeks 0, 3, and 6 with 109 CFU of S. gordonii vaccine strain GP1246 expressing LTB (solid bars) or with the control strain S. gordonii GP246 expressing an unrelated antigen (E7 of HPV-16) (open bars). For the i.g. inoculum, two groups of eight BALB/c mice each were inoculated with live recombinant S. gordonii GP1246 (solid bars) or with control strain GP246 (open bars). Mice were immunized twice (weeks 0 and 4), and each immunization consisted of two doses (24 h apart) of 1010 CFU of live bacteria. Serum samples were collected from animals immunized s.c. and i.g. at weeks 0, 5, and 8 and 0, 4, and 7, respectively. Samples from each animal were titrated in twofold dilutions and analyzed by ELISA for the presence of LTB-specific IgG. Antibody titers are expressed as the reciprocal of the highest serum dilution with an absorbance per hour value of >0.2 after subtraction of the background value. The titer of preimmune sera is also reported (gray bars). Arrows indicate the times of inoculations. Results are expressed as the mean ± SD. Significant differences between vaccine and control animals inoculated s.c. and i.g. were calculated (P = 0.002 and P = 0.004, respectively).
FIG. 3
FIG. 3
LTB-specific serum antibodies after s.c. (A) and i.g. (B) immunizations with recombinant S. gordonii. The concentrations of total and LTB-specific IgG1 and IgG2a antibodies were determined by ELISA using standard curves of mouse myeloma IgG1 and IgG2a. The amounts of LTB-specific IgG1 and IgG2a were normalized to the concentrations of total IgG1 and IgG2a, and results were expressed in micrograms of LTB-specific IgG1 or IgG2a per milligram of total IgG1 or IgG2a, respectively. Serum samples were collected at weeks 0, 5, and 8 (s.c.) and 0, 4, and 7 (i.g.). On the x axes, arrows indicate the times of inoculations.
FIG. 4
FIG. 4
LTB-specific IgA in fecal samples of mice inoculated i.g. Two groups of eight BALB/c mice each were immunized with either the vaccine strain GP1246 (solid bars) or the control strain GP246 (open bars) as described for Fig. 2. Inoculations were performed at weeks 0 and 4. Feces were collected at weeks 0, 2, 4, 5, 6, 7, and 8. To calculate the concentrations of total and LTB-specific IgA, a standard curve of mouse myeloma IgA was used. The concentration of LTB-specific IgA was determined in pools of fecal samples containing 10 μg of total IgA from each sample per ml. The amount of LTB-specific IgA was normalized to the concentration of total IgA and expressed in micrograms of specific IgA per milligram of total IgA. Antigen-specific IgA in pooled preimmune fecal samples is also reported (gray bar).

References

    1. Amin T, Hirst T R. Purification of the B-subunit oligomer of Escherichia coli heat-labile enterotoxin by heterologous expression and secretion in a marine vibrio. Protein Expr Purif. 1994;5:198–204. - PubMed
    1. Apter F M, Michetti P, Winner III L S, Mack J A, Mekalanos J J, Neutra M R. Analysis of the role of antilipopolysaccharide and anti-cholera toxin immunoglobulin A antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun. 1993;61:5279–5285. - PMC - PubMed
    1. Backstrom M, Shahabi V, Johansson S, Teneberg S, Kjellberg A, Miller-Podraza H, Holmgren J, Lebens M. Structural basis for differential receptor binding of cholera and Escherichia coli heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit. Mol Microbiol. 1997;24:489–497. - PubMed
    1. Chamberlain L, Wells J M, Robinson K, Schofield K, Le Page R. Mucosal immunization with recombinant Lactococcus lactis. In: Pozzi G, Wells J M, editors. Gram-positive bacteria. Vaccine vehicles for mucosal immunization. Austin, Tex: RG Landes; 1997. pp. 83–106.
    1. Clements J D, El-Morshidy S. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun. 1984;46:564–569. - PMC - PubMed

Publication types

LinkOut - more resources